Last reviewed · How we verify
Urothelial carcinoma — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| PF-07220060 + PF-07104091 combination dose escalation | pf-07220060-pf-07104091-combination-dose-escalation | Pfizer | Not specified | Not specified | ||
| Pf-06882961 | pf-06882961 | Pfizer | Not specified | Not specified |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Urothelial carcinoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Urothelial carcinoma:
- Urothelial carcinoma treatment updates — RSS
- Urothelial carcinoma treatment updates — Atom
- Urothelial carcinoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Urothelial carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/urothelial-carcinoma. Accessed 2026-06-10.
Related
- Urothelial carcinoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing